Fimepinostat
Fimepinostat, also known by its research code CUDC-907, is a small molecule inhibitor that targets both histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) pathways. It is being investigated for its potential use in the treatment of various cancers, including lymphomas and solid tumors.
Mechanism of Action[edit | edit source]
Fimepinostat functions as a dual inhibitor, simultaneously targeting HDAC and PI3K pathways. The inhibition of HDAC leads to an accumulation of acetylated histones and non-histone proteins, resulting in altered gene expression and induction of apoptosis in cancer cells. The PI3K inhibition disrupts the PI3K/AKT/mTOR signaling pathway, which is crucial for cell growth, proliferation, and survival. By targeting both pathways, fimepinostat aims to exert a synergistic effect, enhancing its anticancer activity.
Clinical Development[edit | edit source]
Fimepinostat is currently undergoing clinical trials to evaluate its efficacy and safety in treating various types of cancer. Early-phase clinical trials have shown promising results, particularly in patients with relapsed or refractory lymphomas. The drug is administered orally, which offers a convenient route of administration for patients.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of fimepinostat includes its absorption, distribution, metabolism, and excretion. It is well-absorbed when taken orally, and it undergoes hepatic metabolism. The drug and its metabolites are primarily excreted via the urine.
Adverse Effects[edit | edit source]
Common adverse effects associated with fimepinostat include fatigue, nausea, diarrhea, and thrombocytopenia. As with other HDAC and PI3K inhibitors, there is a risk of more severe side effects, such as liver toxicity and hyperglycemia, which require careful monitoring during treatment.
Research and Future Directions[edit | edit source]
Ongoing research is focused on optimizing the dosing regimen of fimepinostat and exploring its use in combination with other anticancer agents. Preclinical studies suggest that combining fimepinostat with other targeted therapies or chemotherapeutic agents may enhance its efficacy and overcome resistance mechanisms.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
